TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 30890122

Group type: EXPERIMENTAL
Intervention: 8-week exercise program using stationary bicycles (Mini-bike)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 10-min limbering exercise for 8 weeks (Control)
Number of subjects: 60
Study: 27876220

Group type: EXPERIMENTAL
Intervention: Brief communication skills training module for breaking bad news (BBN)
Number of subjects: 66
Study: 26512597

Group type: EXPERIMENTAL
Intervention: PET-CT scan at 9 months (PET-CT9) after the start of radiation treatment
Number of subjects: 92

Group type: COMPARATOR
Intervention: Standard follow-up without PET-CT9 (Control Group B)
Number of subjects: 92
Study: 25551791

Group type: EXPERIMENTAL
Intervention: Web-based quality improvement (QI) system with indicator-based performance feedback and educational outreach visits
Number of subjects: 18
Study: 22843114

Group type: EXPERIMENTAL
Intervention: Moderate aerobic exercise 45-60 min, 4 days per week, through 36 weeks gestation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Sedentary control group
Number of subjects: 62
Study: 19242343

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU once weekly, subcutaneously (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU once weekly, intravenously (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 15,000 IU every other day, subcutaneously (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 15,000 IU every other day, intravenously (group D)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU on day 1 and 3, subcutaneously (group E)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Epoetin alfa 40,000 IU on day 1 and 3, intravenously (group F)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: All dosing regimens of epoetin alfa
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Adverse events reported
Number of subjects: 60
Study: 17558821

Group type: EXPERIMENTAL
Intervention: Degree of craving measured by the Questionnaire on Smoking Urges
Number of subjects: 34

Group type: EXPERIMENTAL
Intervention: Cigarettes smoked per day
Number of subjects: 34
Study: 15679127

Group type: EXPERIMENTAL
Intervention: 3.0 mg of tetracaine
Number of subjects: 30

Group type: COMPARATOR
Intervention: 6.0 mg of tetracaine
Number of subjects: 30
Study: 12175983

Group type: EXPERIMENTAL
Intervention: Focused breast skills workshop (2 hours)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Traditional ambulatory teaching (4 hours)
Number of subjects: 124
Study: 9615801

Group type: EXPERIMENTAL
Intervention: MTH‐68/B vaccine treatment
Number of subjects: 84

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 84
Study: 8087786

Group type: EXPERIMENTAL
Intervention: Conformal three-dimensional (3D) radiation treatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional radiation treatment
Number of subjects: 0
Study: 2514676

Group type: EXPERIMENTAL
Intervention: Cicletanine 100 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cicletanine 150 mg/day
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Cicletanine 200 mg/day
Number of subjects: 88
Study: 7193520

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum on Day 1
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Corynebacterium parvum on Day 14
Number of subjects: 40

Group type: COMPARATOR
Intervention: Doxorubicin and cisplatin (no specific day mentioned)
Number of subjects: 40
Study: 31060757

Group type: EXPERIMENTAL
Intervention: Balloon pulmonary angioplasty (BPA)
Number of subjects: 15
Study: 29339901

Group type: EXPERIMENTAL
Intervention: IRGO (Isocentric Reciprocating Gait Orthosis)
Number of subjects: 9

Group type: COMPARATOR
Intervention: IRGO without reciprocating link
Number of subjects: 9
Study: 26510526

Group type: EXPERIMENTAL
Intervention: Astym therapy
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Placebo (sham Astym treatment)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 45
Study: 23665753

Group type: EXPERIMENTAL
Intervention: Active movements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Passive movements
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants' own movements as temporally delayed distractors
Number of subjects: 0
Study: 22341059

Group type: EXPERIMENTAL
Intervention: 4% articaine with 1:100,000 epinephrine
Number of subjects: 100

Group type: COMPARATOR
Intervention: 2% lidocaine with 1:80,000 epinephrine
Number of subjects: 100
Study: 20452716

Group type: EXPERIMENTAL
Intervention: Total intravenous anaesthesia (TIVA)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 53
Study: 17565634

Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Rabeprazole 10 mg
Number of subjects: 36
Study: 15810472

Group type: EXPERIMENTAL
Intervention: Cotton swab
Number of subjects: 318

Group type: COMPARATOR
Intervention: Dacron swab
Number of subjects: 318

Group type: COMPARATOR
Intervention: Cytologic brush
Number of subjects: 318
Study: 12150616

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 332
Study: 10102601

Group type: COMPARATOR
Intervention: 5% lidocaine ointment
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: EMLA cream
Number of subjects: 10
Study: 7788259

Group type: EXPERIMENTAL
Intervention: Intravesical methylene blue staining (1% solution)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Random biopsy
Number of subjects: 39
Study: 2360738

Group type: EXPERIMENTAL
Intervention: Brachial artery pressure monitoring
Number of subjects: 170

Group type: COMPARATOR
Intervention: Radial artery pressure monitoring
Number of subjects: 170
Study: 7198462

Group type: EXPERIMENTAL
Intervention: Plafibride at 800 mg/d
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plafibride at 1600 mg/d
Number of subjects: 0

Group type: COMPARATOR
Intervention: Alufibrate (control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Plafibride and Alufibrate
Number of subjects: 0
Study: 31792007

Group type: EXPERIMENTAL
Intervention: Differentially expressed genes (DEGs) identified at E14, E18, E28 stages
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Functional classification of DEGs
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Specific GO terms identified
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Clustering of DEGs
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: KEGG pathways identified
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Selected DEGs for verification
Number of subjects: 9
Study: 30822124

Group type: EXPERIMENTAL
Intervention: Dynamic augmented ACL suture repair
Number of subjects: 48

Group type: COMPARATOR
Intervention: ACL reconstruction (single-bundle, all-inside, semitendinosus technique)
Number of subjects: 48
Study: 28792112

Group type: EXPERIMENTAL
Intervention: VSP Er:YAG laser resurfacing (400 mJ in short pulse mode with 50% overlapping and 2.2 J/cm2 in smooth mode)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: VSP Er:YAG laser resurfacing (two passes of 400 mJ in short pulse mode with 50% overlapping)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 21
Study: 25867447

Group type: EXPERIMENTAL
Intervention: Active treatment (nicotine patch, nicotine lozenge, bupropion SR, patch and lozenge, or bupropion SR and lozenge)
Number of subjects: 1433

Group type: EXPERIMENTAL
Intervention: Patch and lozenge combination
Number of subjects: 1433

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1433
Study: 24028629

Group type: EXPERIMENTAL
Intervention: Saccharomyces boulardii supplementation (250 mg/day)
Number of subjects: 271

Group type: COMPARATOR
Intervention: Control group (no S. boulardii supplementation)
Number of subjects: 271
Study: 21301952

Group type: EXPERIMENTAL
Intervention: Protocol for an Office‐based Nurse‐administered Intervention (PONI) administered on-site by trained nurses over the course of 3-6 months.
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Initial symptom severity
Number of subjects: 80
Study: 19237249

Group type: EXPERIMENTAL
Intervention: Opioid therapy (group 3)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No opioid therapy (group 2)
Number of subjects: 58

Group type: COMPARATOR
Intervention: No pain or opioid therapy (group 1)
Number of subjects: 58
Study: 17249848

Group type: EXPERIMENTAL
Intervention: Garenoxacin 600 mg as intact tablets
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Garenoxacin 600 mg as crushed tablets via NG tube
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Garenoxacin 600 mg as crushed tablets via NG tube with concomitant enteral feeding (Osmolite; 600 mL at 100 mL/h)
Number of subjects: 18
Study: 15236891

Group type: EXPERIMENTAL
Intervention: 24 h intravenous hydration
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intravenous hydration (Control)
Number of subjects: 0
Study: 11597795

Group type: EXPERIMENTAL
Intervention: No PORT for low-risk group (n = 31)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 57.6 Gy during 6.5 weeks for intermediate-risk group (n = 31)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 63 Gy during 5 weeks for high-risk group (n = 76)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: 63 Gy during 7 weeks for high-risk group (n = 75)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Concomitant boost technique (2-week reduction in PORT duration)
Number of subjects: 213

Group type: EXPERIMENTAL
Intervention: Cumulative duration of combined therapy
Number of subjects: 213
Study: 9145729

Group type: EXPERIMENTAL
Intervention: Amoxicillin/clavulanate (875/125 mg) every 12 hours
Number of subjects: 557

Group type: COMPARATOR
Intervention: Amoxicillin/clavulanate (500/125 mg) every 8 hours
Number of subjects: 557
Study: 7703511

Group type: EXPERIMENTAL
Intervention: Nifedipine 20 mg sublingually
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Isosorbide dinitrate 5 mg
Number of subjects: 16
Study: 3034316

Group type: EXPERIMENTAL
Intervention: enalapril maleate 10 mg orally
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: enalapril maleate 5 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: enalaprilat 5 mg intravenously
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: oral administration of 10 mg enalapril maleate
Number of subjects: 12
Study: 29423981

Group type: EXPERIMENTAL
Intervention: Practice nurse led health checks
Number of subjects: 11
Study: 26486702

Group type: EXPERIMENTAL
Intervention: Intradermal (ID) influenza vaccine (15 µg)
Number of subjects: 400

Group type: COMPARATOR
Intervention: Intramuscular (IM) influenza vaccine (15 µg)
Number of subjects: 400
Study: 25418440

Group type: EXPERIMENTAL
Intervention: Delayed primary excision (DPE) with adjusted radiation therapy (RT) dose
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Radiation therapy (RT) dose of 36 Gy, 41.4 Gy, or 50.4 Gy based on DPE results
Number of subjects: 161

Group type: COMPARATOR
Intervention: IRS-IV standard treatment without DPE
Number of subjects: 161
Study: 24199974

Group type: EXPERIMENTAL
Intervention: Tai Chi Chuan (TCC) exercise for 3 months, 40 min per session, 7 times per week
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group (normal subjects)
Number of subjects: 42
Study: 20007415

Group type: EXPERIMENTAL
Intervention: Room temperature local anaesthetic
Number of subjects: 50

Group type: COMPARATOR
Intervention: Refrigerated local anaesthetic
Number of subjects: 50
Study: 18806105

Group type: EXPERIMENTAL
Intervention: Iron + Folic Acid + Retinol + Riboflavin (IFAB)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Iron + Folic Acid + Retinol (IFA)
Number of subjects: 366

Group type: EXPERIMENTAL
Intervention: Iron + Folic Acid + Riboflavin (IFB)
Number of subjects: 366

Group type: COMPARATOR
Intervention: Iron + Folic Acid (IF)
Number of subjects: 366
Study: 15684258

Group type: EXPERIMENTAL
Intervention: Lidocaine 0.5 mg.kg(‐1)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.0 mg.kg(‐1)
Number of subjects: 320

Group type: EXPERIMENTAL
Intervention: Lidocaine 1.5 mg.kg(‐1)
Number of subjects: 320

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study: 11850268

Group type: EXPERIMENTAL
Intervention: Liposomal amphotericin B (AmBisome) - 2 mg/kg body weight
Number of subjects: 0

Group type: COMPARATOR
Intervention: Amphotericin B deoxycholate (AMB-DOC) - 0.6 mg/kg body weight
Number of subjects: 0
Study: 10477253

Group type: EXPERIMENTAL
Intervention: Intervention (counseling to reduce child's intake of saturated fat and cholesterol)
Number of subjects: 1062

Group type: COMPARATOR
Intervention: Control (brief dietary discussion)
Number of subjects: 1062
Study: 8557971

Group type: EXPERIMENTAL
Intervention: Enalapril (20-40 mg/day)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Nifedipine-GITS (30-60 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Aspirin (100 mg/day for 2 weeks)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Indomethacin (75 mg/day for 1 week)
Number of subjects: 18
Study: 1956698

Group type: EXPERIMENTAL
Intervention: Hybrid synthetic polypeptide vaccine containing epitopes from four proteins of Plasmodium falciparum
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: HLA phenotyping of low responders
Number of subjects: 185
Study: 6215831

Group type: EXPERIMENTAL
Intervention: Desipramine 75 mg b.i.d.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Zimelidine 100 mg b.i.d.
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Both treatments (Zimelidine and Desipramine)
Number of subjects: 16
Study: 31818340

Group type: EXPERIMENTAL
Intervention: Clinical care for symptomatic RTIs
Number of subjects: 60678

Group type: EXPERIMENTAL
Intervention: Healthcare utilization for common cold, influenza, and acute upper RTIs
Number of subjects: 60678

Group type: EXPERIMENTAL
Intervention: Healthcare utilization rates
Number of subjects: 60678

Group type: EXPERIMENTAL
Intervention: Clinical interventions for RTIs
Number of subjects: 60678
Study: 28509614

Group type: EXPERIMENTAL
Intervention: Telephone follow-up calls (TFU) within 72 hours after discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: No intervention (control group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telephone follow-up calls (TFU)
Number of subjects: 0
Study: 26938214

Group type: EXPERIMENTAL
Intervention: Oral flucloxacillin
Number of subjects: 113

Group type: EXPERIMENTAL
Intervention: Topical fusidic acid
Number of subjects: 113

Group type: COMPARATOR
Intervention: Oral and topical placebos
Number of subjects: 113
Study: 24746844

Group type: EXPERIMENTAL
Intervention: Paramedics' experiences and challenges in conducting out-of-hospital stroke trials
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Facilitators identified
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Barriers identified
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Motivation of paramedics
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Overall feasibility of ultra-acute stroke research
Number of subjects: 14
Study: 22549668

Group type: EXPERIMENTAL
Intervention: Decompression splints
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 20
Study: 19417580

Group type: EXPERIMENTAL
Intervention: efavirenz plus two NRTIs
Number of subjects: 753

Group type: EXPERIMENTAL
Intervention: lopinavir/r plus two NRTIs
Number of subjects: 753

Group type: COMPARATOR
Intervention: lopinavir/r plus efavirenz (NRTI-sparing)
Number of subjects: 753

Group type: COMPARATOR
Intervention: NRTI-sparing regimen
Number of subjects: 753
Study: 16575724

Group type: EXPERIMENTAL
Intervention: Doxycycline (200 mg/day) for 3 weeks
Number of subjects: 44

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Doxycycline
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Doxycycline and Placebo
Number of subjects: 44
Study: 14644780

Group type: EXPERIMENTAL
Intervention: Short-axis (SA) approach
Number of subjects: 17

Group type: COMPARATOR
Intervention: Long-axis (LA) approach
Number of subjects: 17
Study: 11013866

Group type: EXPERIMENTAL
Intervention: Obese boys
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group boys
Number of subjects: 35
Study: 8657524

Group type: EXPERIMENTAL
Intervention: Breakfast with 25% of daily phenylalanine allowance and lunch with 30%
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Breakfast with 50% of daily phenylalanine allowance and lunch with 10%
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Breakfast with 75% of daily phenylalanine allowance and lunch with 10%
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Breakfast with unequal distribution of phenylalanine allowance
Number of subjects: 7
Study: 1632391

Group type: EXPERIMENTAL
Intervention: Lovastatin, 40 mg twice daily for 7 to 10 days before PTCA and continued for 6 months.
Number of subjects: 360

Group type: COMPARATOR
Intervention: Placebo for 7 to 10 days before PTCA and continued for 6 months.
Number of subjects: 360
Study: 6475822

Group type: EXPERIMENTAL
Intervention: Zinc supplementation (20 mg zinc added to vitamin and mineral supplements)
Number of subjects: 213

Group type: COMPARATOR
Intervention: Control group (no zinc supplementation)
Number of subjects: 213
Study: 31375452

Group type: EXPERIMENTAL
Intervention: General radiomic signature
Number of subjects: 54

Group type: COMPARATOR
Intervention: Targeted therapy
Number of subjects: 54

Group type: COMPARATOR
Intervention: Nontargeted therapy
Number of subjects: 54
Study: 30518050

Group type: EXPERIMENTAL
Intervention: Walnut consumption (15% of energy) for 2 years
Number of subjects: 149

Group type: COMPARATOR
Intervention: Control group (habitual diet, abstaining from walnuts)
Number of subjects: 149
Study: 27236883

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine combined with electrical stimulation at Baihui (DU20), Yintang (EX-HN3), and Neiguan (PC6) before dexmedetomidine anesthesia.
Number of subjects: 122

Group type: COMPARATOR
Intervention: Dexmedetomidine anesthesia (control group).
Number of subjects: 122
Study: 23417236

Group type: EXPERIMENTAL
Intervention: 2 × 4 mL hylastan
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: 1 × 4 mL hylastan
Number of subjects: 391

Group type: COMPARATOR
Intervention: Steroid (IA methylprednisolone acetate 40 mg)
Number of subjects: 391

Group type: EXPERIMENTAL
Intervention: All treatments (2 × 4 mL hylastan, 1 × 4 mL hylastan, steroid)
Number of subjects: 391
Study: 22331761

Group type: EXPERIMENTAL
Intervention: Test: 0.2 mg misoprostol tablet
Number of subjects: 20

Group type: COMPARATOR
Intervention: Reference: branded misoprostol tablet
Number of subjects: 20
Study: 20655543

Group type: EXPERIMENTAL
Intervention: High-DHA algal oil (∼200 mg/d of DHA)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Vegetable oil (placebo, containing no DHA)
Number of subjects: 0
Study: 17666627

Group type: EXPERIMENTAL
Intervention: Anterior colporrhaphy with tailored low-weight polypropylene mesh
Number of subjects: 202

Group type: COMPARATOR
Intervention: Anterior colporrhaphy without mesh
Number of subjects: 202
Study: 15861352

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Trandolapril
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 12393771

Group type: EXPERIMENTAL
Intervention: Laryngeal tube
Number of subjects: 22

Group type: COMPARATOR
Intervention: Laryngeal mask
Number of subjects: 22
Study: 10196731

Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure readings (2 readings, one at work and one at home, over 3 consecutive days)
Number of subjects: 43

Group type: EXPERIMENTAL
Intervention: Self-measured blood pressure readings (2 readings, one at work and one at home, over 8 or more consecutive days)
Number of subjects: 43
Study: 7777878

Group type: COMPARATOR
Intervention: Alfentanil and placebo (n = 13)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Alfentanil and midazolam (n = 11)
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Meperidine and midazolam (n = 11)
Number of subjects: 35
Study: 2406859

Group type: EXPERIMENTAL
Intervention: Bismuth subsalicylate (300 mg every 30 minutes, total of 2.4 g in eight doses)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 31
Study: 161062

Group type: EXPERIMENTAL
Intervention: Cyphosis gymnastics
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Kinebalneotherapy
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Differentiated rehabilitation
Number of subjects: 87
Study: 31513088

Group type: EXPERIMENTAL
Intervention: Bushen Tiaogan formula (BSTG) plus traditional Chinese medicine-based psychotherapy (TBP)
Number of subjects: 307

Group type: COMPARATOR
Intervention: Placebo plus traditional Chinese medicine-based psychotherapy (TBP)
Number of subjects: 307
Study: 28762354

Group type: EXPERIMENTAL
Intervention: In‐office bleaching with 35% hydrogen peroxide (HP) activated by LED bleaching unit
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Enamel microabrasion (EM) followed by in‐office bleaching with 44% carbamide peroxide gel
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: In‐office bleaching with 5% sodium hypochlorite (5% NaOCl)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Bleaching and microabrasion procedures
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Postoperative satisfaction
Number of subjects: 90
Study: 25633498

Group type: EXPERIMENTAL
Intervention: HO-RUTF
Number of subjects: 141

Group type: COMPARATOR
Intervention: RUTF
Number of subjects: 141
Study: 23463625

Group type: EXPERIMENTAL
Intervention: Capecitabine/oxaliplatin (CapOx) plus bevacizumab
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Dose-modified capecitabine/irinotecan (mCapIri) plus bevacizumab
Number of subjects: 255
Study: 21297287

Group type: EXPERIMENTAL
Intervention: Repetitive arm task
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Functional shoulder measures
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Heart rate (HR) and power output (PO)
Number of subjects: 32
Study: 19815264

Group type: EXPERIMENTAL
Intervention: Shock Wave Lithotripsy (SWL)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Ureteroscopy (URS)
Number of subjects: 200
Study: 16674031

Group type: EXPERIMENTAL
Intervention: Monitored sip test
Number of subjects: 0

Group type: COMPARATOR
Intervention: Routine cautious introduction of fluids
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Monitored sip test and routine cautious introduction of fluids
Number of subjects: 0
Study: 12931937

Group type: EXPERIMENTAL
Intervention: Positive mood group
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Negative mood group
Number of subjects: 214

Group type: EXPERIMENTAL
Intervention: Combined mood subscales
Number of subjects: 214